Target intelligence / Profile preview

Vascular wall calcification

Molecular classification
Other
01

Overview

Vascular wall calcification refers to the pathological deposition of calcium-phosphate mineral in the blood vessel wall, often occurring in the intimal (associated with atherosclerotic plaques and inflammation) and medial layers (common in diabetes and chronic kidney disease). The process involves vascular smooth muscle cells undergoing osteogenic transformation, matrix protein secretion, vesicle-mediated mineralization, and is driven by an imbalance between pro-calcific factors (hyperphosphatemia, inflammation, oxidative stress) and endogenous inhibitors (matrix Gla protein, pyrophosphate, fetuin-A). Vascular calcification contributes to arterial stiffness, hypertension, increased cardiovascular mortality, and loss of vessel compliance, and currently lacks targeted drug therapies. Vascular wall calcification is a clinically significant pathologic process rather than a conventional druggable molecular target. Disease management focuses on the modulation of contributing factors—serum minerals, inflammation, and osteogenic signaling in vascular smooth muscle cells—rather than direct molecular inhibition.

Other names
Vascular calcificationarterial calcificationvascular mineralizationectopic vascular calcification
02

Mechanism of action

Indirect, when using drugs: reducing serum phosphate/calcium levels, inhibiting osteogenic differentiation of smooth muscle cells, inhibition of matrix vesicle release, reduction of oxidative stress/inflammation

03

Biological functions

Mineral homeostasisPathological tissue remodelingLoss of vascular complianceVascular smooth muscle cell osteogenic differentiationRegulation of extracellular matrix mineralization
04

Disease associations

Cardiovascular diseaseChronic kidney diseaseDiabetes mellitusHypertensionAtherosclerosisValvular heart disease
05

Safety considerations

No established therapies; current attempts to manage focus on mineral metabolism modulation (risks with calcium-based binders)Excessive lowering of serum minerals risks hypocalcemia or bone disease
06

Interacting drugs

Some research on phosphate binders

5 more in the full profile.

07

Biomarkers

Imaging (CT calcium scoring)Serum phosphate, calcium, parathyroid hormoneOsteogenic markers in blood or tissue (e.g., alkaline phosphatase, RUNX2, osteopontin)

Beyond the preview

Go deeper on Vascular wall calcification.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vascular wall calcification.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call